Table IV.
Comparison of clinicopathologic characteristics according to mutation profiles identified by Oncomine focus assay.
| Characteristics | No alterations (n=28) | Other alterationsa (n=14) | PIK3CA alterations (n=8) | P-value |
|---|---|---|---|---|
| Male | 19 (68%) | 9 (64%) | 8 (100%) | 0.152 |
| Age, years (range) | 62 (39–84) | 64 (53–91) | 77 (52–89) | 0.156 |
| Differentiation | 0.675 | |||
| Moderate | 14 (50%) | 6 (43%) | 5 (63%) | |
| Poor | 14 (50%) | 8 (57%) | 3 (37%) | |
| TNM T stage | 0.044 | |||
| 2 | 1 (4%) | 3 (21%) | 0 (0%) | |
| 3 | 11 (39%) | 1 (7%) | 1 (12%) | |
| 4a | 16 (57%) | 10 (72%) | 7 (88%) | |
| TNM N stage | 0.892 | |||
| 0 | 5 (18%) | 3 (21%) | 2 (25%) | |
| 1 | 6 (21%) | 3 (21%) | 2 (25%) | |
| 2 | 5 (18%) | 5 (37%) | 2 (25%) | |
| 3a/ | 10 (36%) | 2 (14%) | 2 (25%) | |
| 3b | 2 (7%) | 1 (7%) | 0 (0%) | |
| TNM M stage | 0.702 | |||
| 0 | 27 (96%) | 13 (93%) | 8 (100%) | |
| 1 | 1 (4%) | 1 (7%) | 0 (0%) | |
| Lauren's classification | 0.028b | |||
| 0.076c | ||||
| Diffuse | 10 (36%) | 5 (36%) | 0 (0%) | |
| Intestinal | 16 (57%) | 6 (43%) | 8 (100%) | |
| Mixed | 2 (7%) | 3 (21%) | 0 (0%) |
a
Alternations other than PIK3CA (single nucleotide variant, small insertion, duplication, deletion and amplification) identified by the Oncomine focus assay in the present study.
b
The distribution of Lauren's classification in AGC with PIK3CA alterations vs. AGC with alterations other than PIK3CA.